Founded in 2019, AltrixBio is based on research by Jeff Karp, PhD, and Ali Tavakkoli, MD, of Mass General Brigham and Harvard Medical School. Inspired by the rapid resolution of type 2 diabetes following bariatric surgery, they modified sucralfate—a therapy with over 40 years of clinical use—to replicate these metabolic benefits, creating AJN003, a proprietary, bio-engineered, once-daily oral therapy.
AJN003 forms a temporary barrier in the stomach, duodenum, and jejunum, altering nutrient sensing to trigger a metabolic reset. Preclinical data show it improves insulin resistance and key metabolic hormones (GLP-1, GIP, ghrelin, leptin), driving improved glycemic control and weight loss. As a small molecule with no systemic exposure, AJN003 offers a novel, patent-protected approach to treating type 2 diabetes, obesity, and other metabolic diseases.
The AltrixBio team comprises scientists, clinicians, and business leaders with deep scientific, operational, and commercial expertise.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2019
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was AltrixBio Inc. founded?
AltrixBio Inc. was founded in 2019.
What industry is AltrixBio Inc. in?
AltrixBio Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is AltrixBio Inc. based?
AltrixBio Inc. is headquartered in Boston, United States.
Find investors for your startup like AltrixBio Inc.
Gritt sends AI-personalised outreach to each investor — from your Gmail
